UTH.SG - UNITED THERAPEUTICS CORP.(DEL.R

Stuttgart - Stuttgart Delayed Price. Currency in EUR
114.00
+3.00 (+2.70%)
At close: 8:26PM CET
Stock chart is not supported by your current browser
Previous Close111.00
Open110.00
Bid0.00 x 100000
Ask0.00 x 100000
Day's Range110.00 - 114.00
52 Week Range95.52 - 159.10
Volume0
Avg. Volume0
Market CapN/A
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • PR Newswire8 hours ago

    Faruqi & Faruqi, LLP is Investigating United Therapeutics Corporation (UTHR) on Behalf of its Shareholders

    NEW YORK , Jan. 17, 2018 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential wrongdoing at United Therapeutics Corporation ("United Therapeutics" ...

  • 6 Companies Boosting Revenue and Earnings
    GuruFocus.com12 days ago

    6 Companies Boosting Revenue and Earnings

    Express Scripts tops the list

  • PR Newswire15 days ago

    Corsair Pharma and United Therapeutics Enter into Strategic Collaboration to Advance Novel Treprostinil Prodrugs

    SOUTH SAN FRANCISCO, Calif. and SILVER SPRING, Md., Jan. 3, 2018 /PRNewswire/ -- United Therapeutics Corporation (UTHR), a leading biotechnology company focused on development of therapies for the treatment of pulmonary arterial hypertension (PAH), and Corsair Pharma, Inc., a private biopharmaceutical company developing a transdermal treprostinil prodrug, today announced that they entered into an exclusive license agreement for Corsair's portfolio of patents covering treprostinil prodrugs as well as an equity investment by United Therapeutics in Corsair. Under the terms of the license agreement, United Therapeutics has been granted an exclusive license to Corsair's intellectual property for the development of treprostinil prodrug formulations.

  • PR Newswire21 days ago

    United Therapeutics Corporation To Present At 36th Annual J.P. Morgan Healthcare Conference

    SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Dec. 28, 2017 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that Martine Rothblatt , Ph.D., Chairman and Chief Executive ...

  • Reuters28 days ago

    United Therapeutics to pay $210 million to resolve U.S. kickback probe

    United Therapeutics Corp will pay $210 million to resolve U.S. claims that the drugmaker used a charity as a conduit to illegally cover Medicare patients' out-of-pocket drug costs in order to eliminate price sensitivity and to boost sales. The U.S. Attorney's Office in Massachusetts on Wednesday announced the settlement, one of the first to emerge from an industry-wide investigation into pharmaceutical companies' financial support of patient-assistance charities. Drug companies are prohibited from subsidizing co-payments for patients enrolled in the government healthcare program Medicare.

  • Reuters28 days ago

    United Therapeutics to pay $210 mln to resolve U.S. kickback probe

    United Therapeutics Corp will pay $210 million to resolve U.S. claims that the drugmaker used a charity as a conduit to illegally cover Medicare patients' out-of-pocket drug costs in order to eliminate price sensitivity and to boost sales. The U.S. Attorney's Office in Massachusetts on Wednesday announced the settlement, one of the first to emerge from an industry-wide investigation into pharmaceutical companies' financial support of patient-assistance charities. Drug companies are prohibited from subsidizing co-payments for patients enrolled in the government healthcare program Medicare.

  • MarketWatch28 days ago

    United Therapeutics to pay $210 million to settle government allegations of kickback payments

    United Therapeutics Corp. agreed Wednesday to pay $210 million to settle claims that it paid kickbacks to Medicare patients. The U.S. Attorney's office had alleged that the company violated the Anti-Kickback ...

  • TheStreet.comlast month

    United Therapeutics Gets a Quantitative Upgrade

    Shares look to break out from long basing pattern.

  • Market Realistlast month

    What Analysts Recommend for United Therapeutics in November 2017

    In November 2017, the U.S. Food and Drug Administration (or FDA) granted United Therapeutics’ (UTHR) Adcirca Pediatric exclusivity until May 21, 2018.

  • Market Realistlast month

    How Did United Therapeutics’ Tyvaso and Orenitram Perform in 3Q17?

    In 3Q17, United Therapeutics’ (UTHR) Tyvaso generated revenues of $88.9 million, a ~13% decline on a year-over-year (or YoY) basis and a ~15% decline on a quarter-over-quarter basis.

  • Market Realist2 months ago

    How UTHR’s Remodulin, Adcirca, and Unituxin Performed in 3Q17

    In 3Q17, United Therapeutics' (UTHR) Remodulin reported revenues of $187.3 million, which reflected ~23% growth on a year-over-year (or YoY) basis and ~19% growth on a quarter-over-quarter basis.

  • Market Realist2 months ago

    How United Therapeutics Performed in 3Q17

    In 3Q17, United Therapeutics (UTHR) reported revenues of $445 million, a ~9% increase on a year-over-year (or YoY) basis.

  • American City Business Journals2 months ago

    United Therapeutics gets much-needed reprieve with drug patent

    Silver Spring-based United Therapeutics Corp. will have six more months of commercial exclusivity for Adcirca, one of its leading pulmonary arterial hypertension drugs set to lose part of its patent protection Tuesday. Just a day before the drug's patent was set to expire, the Food and Drug Administration said it would extend pediatric exclusivity to United Therapeutics (UTHR) through May 21 for its Adcirca tablets, which made up nearly a quarter of the local biotech's revenue last year. The FDA's decision, based on study results submitted by Eli Lilly and Co. (LLY), will delay any cheaper, generic version of Adcirca from being approved in the next six months.

  • PR Newswire2 months ago

    United Therapeutics Announces Additional Six Months Of Regulatory Exclusivity For Adcirca®

    SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Nov. 20, 2017 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced that the U.S. Food and Drug Administration (FDA) has granted ...

  • GlobeNewswire2 months ago

    SteadyMed Receives Favorable Ruling from U.S. Court of Appeals for the Federal Circuit

    SAN RAMON, Calif., Nov. 14, 2017-- SteadyMed Ltd., a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral ...

  • ACCESSWIRE3 months ago

    Corporate News Blog - United Therapeutics Receives FDA Approval of Third Generation Nebulizer for Tyvaso Inhalation System

    LONDON, UK / ACCESSWIRE / October 25, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for United Therapeutics Corp. (NASDAQ: UTHR ), following which we ...

  • ACCESSWIRE3 months ago

    United Therapeutics Corporation to Host Earnings Call

    Work NEW YORK, NY / ACCESSWIRE / October 25, 2017 / United Therapeutics Corporation (NASDAQ: UTHR ) will be discussing their earnings results in their Q3 Earnings Call to be held on October 25, 2017 at ...

  • Associated Press3 months ago

    United Therapeutics beats Street 3Q forecasts

    On a per-share basis, the Silver Spring, Maryland-based company said it had profit of $6.27. The results exceeded Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment ...

  • PR Newswire3 months ago

    United Therapeutics Corporation Reports Third Quarter 2017 Financial Results

    SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Oct. 25, 2017 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the third quarter ended September 30, ...

  • American City Business Journals3 months ago

    United Therapeutics lands FDA approval linked to drug at center of patent lawsuits

    The company received FDA approval for its pulmonary hypertension drug Tyvaso back in 2009, and its latest approval is for a new inhalation device – called TD-300/A – to be used with the drug. The patents for Tyvaso are currently being challenged by another company seeking to manufacture and sell a generic version of the drug, and litigation filed by United Therapeutics against that company is pending. Andrew Fisher, chief strategy officer and deputy general counsel at United Therapeutics, confirmed in an email that the litigation against Vanderbilt is still pending.

  • PR Newswire3 months ago

    United Therapeutics Announces FDA Approval Of Third Generation Nebulizer For The Tyvaso® Inhalation System

    SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Oct. 23, 2017 /PRNewswire/ -- United Therapeutics Corporation (UTHR) today announced approval by the U.S. Food and Drug Administration (FDA) of a new inhalation device, called the TD-300/A, for use with Tyvaso® (treprostinil) Inhalation Solution (Tyvaso). Tyvaso was originally approved by the FDA for the treatment of pulmonary arterial hypertension (PAH) in 2009, under a New Drug Application covering a drug-device combination product consisting of Tyvaso drug product, as well as an ultrasonic nebulizer and accessories referred to as the Tyvaso Inhalation System.

  • PR Newswire3 months ago

    United Therapeutics Corporation To Report Third Quarter 2017 Financial Results Before The Market Opens On Wednesday, October 25, 2017

    SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Oct. 19, 2017 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will report its third quarter 2017 financial results ...

  • Market Realist3 months ago

    United Therapeutics’s Net Profit Margins Are Expected to Narrow

    In December 2014, United Therapeutics (UTHR) collaborated with DEKA Research & Development to develop a pre-filled and semi-disposable pump, RemUnity, for the continuous and subcutaneous administration ...

  • Market Realist3 months ago

    Why United Therapeutics’ Revenue May Rise in 2017

    United Therapeutics (UTHR) has completed patient enrolment in its Phase 3 trial BEAT, which aims to evaluate the efficacy and safety of a combination regimen of oral esuberapros plus inhaled Tyvaso in ...

  • Market Realist3 months ago

    Analysts’ Recommendations for United Therapeutics

    In 2Q17, United Therapeutics (UTHR) reported revenue of ~$445 million, representing year-over-year growth of around 8%.